Literature DB >> 6202400

Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas.

Y Masuho, M Zalutsky, R C Knapp, R C Bast.   

Abstract

Two monoclonal antibodies, OC 125 and OC 133, bind to distinct determinants on the surface of human epithelial ovarian carcinoma cell lines. OC 125 and OC 133 recognize determinants on molecules with molecular weights greater than 200,000 and 80,000, respectively. When binding to four different cell lines was compared, apparent affinity constants for OC 125 ranged from 3.1 X 10(9) to 6.0 X 10(7) M-1, whereas those for OC 133 ranged from 1.6 X 10(9) to 8.5 X 10(8) M-1. An estimate of the number of antigenic determinants per cell ranged from 1.0 X 10(7) to 2.8 X 10(5) for OC 125 and from 4.0 X 10(5) to 3.4 X 10(4) for OC 133. Antigenic determinants recognized by OC 125 and OC 133 could be detected in spent culture medium. When radiolabeled OC 125 was incubated with each of four ovarian tumor cell lines, approximately 90% of the antibody remained bound to the tumor cell surfaces for more than 20 hr. Similar binding of OC 133 was observed with three of the four ovarian tumor cell lines. By contrast, greater than 70% of OC 133 antibody was either shed or endocytosed after binding to OVCA 433 cells over the same period. Antigenic modulation was not induced by either antibody interacting with any of the four cell lines. These data suggest that antigen may be lost from the surface of human ovarian carcinoma cells by several different mechanisms and that antigen release is not inconsistent with binding of radiolabeled antibody to the tumor cell surface for prolonged periods.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202400

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Development of new immunoradiometric assay for CA 125 antigen using two monoclonal antibodies produced by immunizing lung cancer cells.

Authors:  M Kunimatsu; K Endo; T Nakashima; T Awaji; T Saga; Y Watanabe; Y Kawamura; H Ohta; M Koizumi; H Sakahara
Journal:  Ann Nucl Med       Date:  1988-11       Impact factor: 2.668

2.  Binding parameters of monoclonal antibodies reacting with ovarian carcinoma ascites cells.

Authors:  M J Mattes; K O Lloyd; J L Lewis
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.

Authors:  Y J Lidor; K C O'Briant; F J Xu; T C Hamilton; R F Ozols; R C Bast
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

4.  Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody.

Authors:  C Y Lee; K W Chen; F S Sheu; A Tsang; K C Chao; H T Ng
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Purification and immunochemical characterization of ascitic fluid glycoproteins containing certain tumor-associated and blood group antigen markers.

Authors:  M Venegas; L Liu; L Lovell; L E Davis; B Anderson; T Wilbanks; M Hass; G Manderino; H Rittenhouse
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

6.  Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines.

Authors:  E Sariban; N M Sitaras; H N Antoniades; D W Kufe; P Pantazis
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

7.  In vitro evaluation of cisplatin interaction with doxorubicin or 4-hydroperoxycyclophosphamide against human gynecologic cancer cell lines.

Authors:  M J Xu; D S Alberts; R Liu; A Leibovitz; Y Liu
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Monoclonal antibodies against native ovarian tumor cells: specificity and characterization of the antigen. A preliminary report.

Authors:  L Wasserman; A Neri; B Kaplan; Y Manor; M Galli; B Hardy
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.

Authors:  M Apiranthitou-Drogari; C Paganin; S Bernasconi; G Losa; A Maneo; N Colombo; A Mantovani; P Allavena
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Changes in CA125 release and surface expression caused by drugs in uterine cervix adenocarcinoma cells.

Authors:  T Nakai; H Sakahara; K Endo; M Shirato; H Kobayashi; M Hosono; T Saga; M Sakamoto; J Konishi
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.